As filed with the Securities and Exchange
Commission on August 9, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
____________________
OPGEN, INC.
(Exact Name of Registrant as Specified in
Its Charter)
|
Delaware
|
06-1614015
|
|
(State or Other Jurisdiction of
|
(I.R.S. Employer
|
|
Incorporation or Organization)
|
Identification Number)
|
9717 Key West Avenue, Suite 100
Rockville, MD 20850
(240) 813-1260
(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)
____________________
Timothy C. Dec
Chief Financial Officer
9717 Key West Avenue, Suite 100
Rockville, MD 20850
(240) 813-1260
(Name, Address, Including Zip Code, and Telephone Number,
Including Area Code, of Agent For Service)
____________________
With a copy to:
Peter Jaslow, Esquire
Ballard Spahr LLP
1735 Market Street, 51st Floor
Philadelphia, PA 19103
(215) 665-8500
____________________
Approximate date of commencement of proposed sale to the public:
From time to time after this registration statement becomes effective.
If the only securities
being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. [_]
If any of the
securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. [X]
If this form is
filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [_]
If this form is
a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. [_]
If this form is
a registration statement filed pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. [_]
If this form is
a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities
or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. [_]
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and
“emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):
|
Large Accelerated Filer [_]
|
|
Accelerated Filer [_]
|
|
|
Non-Accelerated Filer [X]
|
|
Smaller Reporting Company [X]
|
|
|
|
|
Emerging Growth Company [__]
|
|
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 7(a)(2)(B) of the Securities Act. [_]
__________________
CALCULATION OF REGISTRATION
FEE
|
Title of Securities to be Registered(1)
|
Amount to be Registered (2)(3)
|
Proposed Maximum Offering Price Per Share(3)
|
Proposed Maximum Aggregate Offering Price(3)
|
Amount of Registration Fee(4)
|
|
Common Stock, par value $0.01 per share
|
|
|
|
|
|
Preferred Stock, par value $0.01 per share
|
|
|
|
|
|
Warrants
|
|
|
|
|
|
Units
|
|
|
|
|
|
Total
|
|
|
$150,000,000.00
|
$16,365.00
|
|
|
(1)
|
This registration statement also covers (i) common stock and preferred stock that may be issued upon
exercise of warrants and (ii) such indeterminate amount of securities as may be issued in exchange for or upon conversion of, as the case
may be, the securities registered hereunder. In addition, securities hereunder may be sold separately or as units with other securities
registered hereunder.
|
|
|
(2)
|
An indeterminate number of securities is being registered as may at various times be issued at indeterminate
prices, with an aggregate public offering price not to exceed $150,000,000. Pursuant to Rule 416 under the Securities Act of 1933, as
amended (the “Securities Act”), the securities being registered hereunder include such indeterminate number of shares of common
stock as may be issuable with respect to the securities being registered hereunder as a result of stock splits, stock dividends or similar
transactions or events.
|
|
|
(3)
|
Pursuant to General Instruction II.D of Form S-3, the table lists each class of securities being registered
and the aggregate proceeds to be raised but does not specify the amount to be registered, proposed maximum offering price per share, and
the proposed maximum aggregate offering price by each class of securities registered.
|
|
|
(4)
|
Estimated solely for the purpose of calculating the registration fee in accordance
with Rule 457(o) under the Securities Act.
|
The registrant hereby amends this registration statement on such
date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states
that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933,
as amended, or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
The information in this prospectus is not complete and
may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is
effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state
where the offer or sale is not permitted.
Subject to Completion, Dated
August 9, 2021
PROSPECTUS
Common Stock
Preferred Stock
Warrants
Units
____________________
We may offer and sell from time to time, in one or more offerings,
up to $150,000,000 of any combination of securities described in this prospectus, in one or more classes or series and in amounts, at
prices and on terms that we will determine at the time of the offerings.
This prospectus describes the general manner in which our securities
may be offered using this prospectus. Each time we sell securities pursuant to this prospectus, we will provide the specific terms of
the securities offered in a supplement to this prospectus. The prospectus supplements will also describe the specific manner in which
we will offer securities and may also supplement, update or amend information contained in this prospectus. You should read this prospectus
and any related prospectus supplement carefully before you invest in our securities.
The securities being registered for the account of the company may
be sold on a delayed or continuous basis directly by us, through dealers, agents or underwriters designated from time to time, or through
any combination of these methods. The prospectus supplements to this prospectus will provide the specific terms of the plan of distribution.
If any dealers, agents or underwriters are involved in the sale of securities in respect of which this prospectus is being delivered,
we will disclose their names and the nature of our arrangements with them in any prospectus supplement.
Our common stock is traded on the NASDAQ Capital Market under the
symbol “OPGN.” On August 9, 2021, the closing price of our common stock was $2.57 per share.
____________________
Investing in our securities involves a
high degree of risk. See “Risk Factors” beginning on page 2 of this prospectus and any similar heading in any prospectus
supplement or other documents that are incorporated by reference into this prospectus.
____________________
This prospectus may not be used to offer
or sell securities unless accompanied by a prospectus supplement for the securities being sold.
Neither the Securities and Exchange Commission
nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.
____________________
The date of this Prospectus is , 2021.
TABLE OF
CONTENTS
Page
|
ABOUT THIS PROSPECTUS
|
ii
|
|
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENT
|
iii
|
|
PROSPECTUS SUMMARY
|
1
|
|
RISK FACTORS
|
2
|
|
USE OF PROCEEDS
|
3
|
|
PLAN OF DISTRIBUTION
|
4
|
|
DESCRIPTION OF SECURITIES
|
6
|
|
LEGAL MATTERS
|
15
|
|
EXPERTS
|
15
|
|
WHERE YOU CAN FIND ADDITIONAL INFORMATION
|
15
|
|
INCORPORATION BY REFERENCE
|
15
|
ABOUT THIS PROSPECTUS
This prospectus is part of a “shelf” registration statement
that we filed with the U.S. Securities and Exchange Commission, or SEC. By using a shelf registration statement, we may, from time to
time, issue any combination of the securities described in this prospectus in one or more offerings up to an aggregate maximum offering
price of $150,000,000. This prospectus sets forth the certain terms of the securities that we may offer. Each time we sell any of our
securities described in this prospectus, we will provide a prospectus supplement that will contain more specific information about the
offering and the terms of the securities being sold. We may also add, update or change in the prospectus supplement any of the information
contained in this prospectus or the documents incorporated by reference.
This prospectus provides you with a general description of the company
and our common stock. For further information about our business and our securities, you should refer to the registration statement and
the reports incorporated by reference in this prospectus, as described in “Where You Can Find Additional Information.”
You should rely only on the information contained in this prospectus
and in any prospectus supplement (including in any documents incorporated by reference herein or therein). We have not authorized anyone
to provide you with any different information. If anyone provides you with different or inconsistent information, you should not rely
on it.
This prospectus is not an offer to sell securities in any state
where the offer or solicitation is not permitted. We are offering to sell our common stock, and seeking offers to buy, only in jurisdictions
where offers and sales are permitted.
You should assume that the information in this prospectus or any
prospectus supplement is accurate only as of the date of this prospectus or any prospectus supplement and that any information we have
incorporated herein by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of
delivery of this prospectus, any prospectus supplement or any sale of any security.
We further note that the representations, warranties and covenants
made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in the accompanying prospectus
were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among
the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations,
warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should
not be relied on as accurately representing the current state of our affairs.
This prospectus may not be used to consummate sales of our securities,
unless it is accompanied by a prospectus supplement. To the extent there are inconsistencies between any prospectus supplement, this prospectus
and any documents incorporated by reference, the document with the most recent date will control.
We and our subsidiaries own various U.S. federal trademark registrations
and applications and unregistered trademarks and servicemarks, including OpGen®, Acuitas®, Acuitas Lighthouse®, AdvanDx®,
Curetis®, Unyvero®, ARES® and ARES GENETICS®. All other trademarks, servicemarks or trade names referred to in this prospectus
are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are sometimes referred
to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will
not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies’
trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies, products or services.
SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS
This prospectus contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and
Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements
of historical fact, included or incorporated in this prospectus regarding our strategy, future operations, collaborations, intellectual
property, cash resources, financial position, future revenues, projected costs, prospects, plans, and objectives of management are forward-looking
statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,”
“intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,”
“continue,” “will,” and “would” and similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words.
We have based these forward-looking statements
on our current expectations and projections about future events and trends that we believe may affect our financial condition, results
of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements
are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors.”
In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances included herein may not occur, and
actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these
uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not
limited to, statements about:
|
|
·
|
our ability to integrate the OpGen, Curetis, and Ares Genetics businesses;
|
|
|
·
|
receipt of regulatory clearance of our submitted 510(k) pre-market submission for our Acuitas AMR Gene
Panel test for use with bacterial isolates;
|
|
|
·
|
the impact of the COVID-19 pandemic on our business and operations;
|
|
|
·
|
our use of proceeds from capital financing transactions;
|
|
|
·
|
the completion of our development efforts for the Unyvero UTI and IJI panels, Unyvero A30 RQ
platform, Aresdb and Acuitas Lighthouse Software, and the timing of regulatory submissions;
|
|
|
·
|
our ability to sustain or grow our customer base for our current research
use only testing products;
|
|
|
·
|
regulations and changes in laws or regulations applicable to our business,
including regulation by the FDA;
|
|
|
·
|
our liquidity and working capital requirements, including our cash requirements
over the next 12 months;
|
|
|
·
|
anticipated trends and challenges in our business and the competition that
we face;
|
|
|
·
|
the execution of our business plan and our growth strategy;
|
|
|
·
|
our expectations regarding the size of and growth in potential markets;
|
|
|
·
|
our opportunity to successfully enter into new collaborative or strategic
agreements;
|
|
|
·
|
our ability to maintain compliance with the ongoing listing requirements
for the Nasdaq Capital Market;
|
|
|
·
|
compliance with the U.S. and international regulations applicable to our
business; and
|
|
|
·
|
our expectations regarding future revenue and expenses.
|
Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. In addition, neither we
nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. These risks
should not be construed as exhaustive and should be read in conjunction with our other disclosures, including but not limited to the risks
described under the heading “Risk Factors.” Other risks may be described from time to time in our filings made under the securities
laws. New risks emerge from time to time. It is not possible for our management to predict all risks. All forward-looking statements in
this prospectus speak only as of the date made and are based on our current beliefs and expectations. We undertake no obligation to update
or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
PROSPECTUS SUMMARY
This summary highlights information contained
in greater detail elsewhere in this prospectus. This summary is not complete and does not contain all of the information you should consider
in making your investment decision. You should read the entire prospectus carefully before making an investment in our securities. You
should carefully consider, among other things, our financial statements and the related notes and the sections entitled “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in, or
incorporated by reference into, this prospectus. When we refer to OpGen, Inc., and its subsidiaries, we use the terms “OpGen,”
“the Company,” “us,” “we” and “our.”
OpGen Overview
We are a
precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. Along with
subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide
clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the
spread of infections caused by multidrug-resistant microorganisms, or MDROs. Our current product portfolio includes Unyvero, Acuitas AMR
Gene Panel, Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics
solutions for antibiotic response prediction.
Our focus is on our combined
broad portfolio of products, which include high impact rapid diagnostics and bioinformatics to interpret AMR genetic data. We currently
expect to focus on the following products for lower respiratory infection, urinary tract infection and invasive joint infection:
|
|
·
|
The Unyvero Lower Respiratory Tract, or LRT, test is the first U.S. Food and Drug Administration, or
FDA, cleared test that can be used for the detection of more than 90% of common causative agents of hospitalized pneumonia. According
to the National Center for Health Statistics (2018), pneumonia is a leading cause of admissions to the hospital and is associated with
substantial morbidity and mortality. The Unyvero LRT automated test detects 19 pathogens within less than five hours, with approximately
two minutes of hands-on time and provides clinicians with a comprehensive overview of 10 genetic antibiotic resistance markers. We are
also commercializing the Unyvero LRT BAL test for testing bronchoalveolar lavage, or BAL, specimens from patients with lower respiratory
tract infections following FDA clearance received by Curetis in December 2019. The Unyvero LRT BAL automated test simultaneously detects
20 pathogens and 10 antibiotic resistance markers, and it is the first and only FDA-cleared panel that also includes Pneumocystis jirovecii,
a key fungal pathogen often found in immunocompromised patients that can be difficult to diagnose, as the 20th pathogen on the panel.
We believe the Unyvero LRT and LRT BAL tests have the ability to help address a significant, previously unmet medical need that causes
over $10 billion in annual costs for the U.S. healthcare system, according to the Centers for Disease Control, or CDC.
|
|
|
·
|
The Unyvero Urinary Tract Infection, or UTI, test which is CE-IVD marked in Europe is currently being
made available to laboratories in the U.S. as a research use only or RUO kit. The test detects a broad range of pathogens as well as antimicrobial
resistance markers directly from native urine specimens. As part of our portfolio strategy update on October 13, 2020, we have decided
to proceed with the analytical and clinical performance evaluation including clinical trials required for a subsequent U.S. FDA submission.
|
|
|
·
|
The Unyvero Invasive Joint Infection, or IJI, test, which is a variant developed for the U.S. market
based on the CE-IVD-marked European Unyvero ITI test, has also been selected for analytical and clinical performance evaluation including
clinical trials towards a future U.S. FDA submission. Microbial diagnosis of IJI is difficult because of challenges in sample collection,
usually at surgery, and patients being on prior antibiotic therapy which minimizes the chances of recovering viable bacteria. We believe
that Unyvero IJI could be useful in identifying pathogens as well as their AMR markers to help guide optimal antibiotic treatment for
these patients.
|
|
|
·
|
The Acuitas AMR Gene Panel (Isolates) is currently pending final FDA review and a potential clearance
decision. The FDA recently notified us that completion of the FDA’s review would require additional time due to the COVID-19 pandemic
and ongoing public health crisis. The FDA also informed us that it currently expects to complete its review by the end of August 2021
but explained it still does not commit to any MDUFA timelines and that its timelines can be affected by various factors, including the
FDA’s other workload and public health priorities. Once FDA cleared, we expect to commercialize the Acuitas AMR Gene Panel for isolates
more broadly to customers in the United States. The Acuitas AMR Gene Panel (Urine) test has been discontinued as part of the October 13,
2020 portfolio and pipeline strategy review.
|
|
|
·
|
We are also developing novel bioinformatics tools and solutions to accompany or augment our current
and potential future IVD products and may seek regulatory clearance for such bioinformatics tools and solutions to the extent they would
be required either as part of our portfolio of IVD products or even as a standalone bioinformatics product.
|
Company Information
OpGen, Inc. was incorporated in Delaware in
2001. On July 14, 2015, we acquired AdvanDx, Inc., a Delaware corporation, as a wholly-owned subsidiary in a merger transaction. On September
3, 2019, we formed Crystal GmbH for the sole purpose of completing our business combination with Curetis GmbH, which closed on April 1,
2020. Our principal executive office is located at 9717 Key West Avenue, Suite 100, Rockville, MD 20850, and our telephone number is (240)
813-1260. We also have operations in Germany and Austria. Our website address is www.opgen.com. We do not incorporate the information
on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through,
our website as part of this prospectus.
RISK FACTORS
Investing in our securities involves substantial
risks. In addition to other information contained in this prospectus and any accompanying prospectus supplement, before investing in our
securities, you should carefully consider the risks described below and under the heading “Risk Factors” in our Annual Report
on Form 10-K or in our most recent Quarterly Report on Form 10-Q, as they may be amended, and in any other documents incorporated by reference
into this prospectus, as updated by our future filings. These risks are not the only ones faced by us. Additional risks not known or that
are deemed immaterial could also materially and adversely affect our financial condition, results of operations, our products, business
and prospects. Any of these risks might cause you to lose all or a part of your investment.
OpGen’s Certificate of Incorporation provides that the
Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between the Company and
its stockholders, which could limit its stockholders' ability to obtain a favorable judicial forum for disputes with the Company or its
directors, officers or other employees.
OpGen’s Certificate of Incorporation provides
that, unless OpGen consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be
the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of OpGen, (ii) any action asserting a claim
of breach of a fiduciary duty owed by any director, officer or other employee of OpGen or its stockholders, (iii) any action asserting
a claim arising pursuant to any provision of the DGCL or the Company’s Certificate of Incorporation or Bylaws, or (iv) any action
asserting a claim governed by the internal affairs doctrine. This exclusive forum provision is intended to apply to claims arising under
Delaware state law and would not apply to claims brought pursuant to the Securities Act or Exchange Act, or any other claim for which
the federal courts have exclusive jurisdiction. The exclusive forum provision in OpGen’s Certificate of Incorporation will not relieve
OpGen of its duties to comply with the federal securities laws and the rules and regulations thereunder, and stockholders of OpGen will
not be deemed to have waived OpGen’s compliance with these laws, rules and regulations.
This exclusive forum provision may limit a stockholder’s ability
to bring a claim in a judicial forum of its choosing for disputes with OpGen or its directors, officers or other employees, which may
discourage lawsuits against OpGen and its directors, officers and other employees. In addition, stockholders who do bring a claim in the
Court of Chancery of the State of Delaware could face additional litigation costs in pursuing any such claim, particularly if they do
not reside in or near Delaware. The Court of Chancery of the State of Delaware may also reach different judgments or results than would
other courts, including courts where a stockholder would otherwise choose to bring the action, and such judgments or results may be more
favorable to OpGen than to its stockholders. However, the enforceability of similar exclusive forum provisions in other companies’
certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find this type of provision
to be inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings. If a court were to
find the exclusive forum provision contained in OpGen’s Certificate of Incorporation to be inapplicable or unenforceable in an action,
OpGen might incur additional costs associated with resolving such action in other jurisdictions.
USE OF PROCEEDS
Unless otherwise indicated in the applicable
prospectus supplement, we intend to use the net proceeds from the sale of our securities under this prospectus to: (i) support research
and development and regulatory activities in support of our FDA 510(k) submission for the Acuitas AMR Gene Panel test for isolates; (ii)
commercialize our products with a focus on the Unyvero platform and diagnostic tests, and the Acuitas AMR Gene Panel test for isolates;
(iii) support further development and commercialization of the Ares Genetics database and Acuitas Lighthouse Software; (iv) support directed
sales and marketing efforts to the customers and collaborators for our products and services, (v) repay outstanding indebtedness, and
(vi) invest in manufacturing and operations infrastructure to support sales of products. We intend to use the remaining net proceeds for
working capital and other general corporate purposes.
Each time we issue securities, we will provide
a prospectus supplement that will contain information about how we intend to use the proceeds from each such offering.
We cannot guarantee that we will receive any
proceeds in connection with any offering hereunder because we may choose not to issue any of the securities covered by this prospectus.
PLAN OF DISTRIBUTION
Primary Offerings by the Company
We may sell securities registered hereunder:
|
|
·
|
directly to purchasers;
|
|
|
·
|
through registered direct offerings;
|
|
|
·
|
through “at the market” offerings, within the meaning of Rule 415(a)(4) of the Securities
Act, to or through a market maker or into an existing trading market on an exchange or otherwise; or
|
|
|
·
|
through a combination of any of these methods or any other method permitted by law.
|
In addition, we may issue the securities as
a dividend or distribution or in a subscription rights offering to our existing security holders.
We may directly solicit offers to purchase our
securities, or agents may be designated to solicit such offers. In the prospectus supplement relating to such offering, we will name any
agent that could be viewed as an underwriter under the Securities Act and describe any commissions that we must pay to any such agent.
Any such agent will be acting on a best efforts basis for the period of its appointment or, if indicated in the applicable prospectus
supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any of these
methods or other methods described in the applicable prospectus supplement.
The distribution of our securities may be effected
from time to time in one or more transactions:
|
|
·
|
at a fixed price, or prices, which may be changed from time to time;
|
|
|
·
|
at market prices prevailing at the time of sale;
|
|
|
·
|
at prices related to such prevailing market prices; or
|
Each prospectus supplement will describe the
method of distribution of the securities sold hereunder and any applicable restrictions.
The prospectus supplement with respect to securities
of a particular series will describe the terms of the offering of the securities, including the following:
|
|
·
|
the name of the agent or any underwriters, if any;
|
|
|
·
|
the public offering or purchase price;
|
|
|
·
|
any discounts and commissions to be allowed or paid to the agent or underwriters;
|
|
|
·
|
all other items constituting underwriting compensation;
|
|
|
·
|
any discounts and commissions to be allowed or paid to dealers; and
|
|
|
·
|
any exchanges on which the securities will be listed.
|
If any underwriters or agents are used in the
sale of our securities in respect of which this prospectus is delivered, we will enter into an underwriting agreement, sales agreement
or other agreement with them at the time of sale to them, and we will set forth in the prospectus supplement relating to such offering
the names of the underwriters or agents and the terms of the related agreement with them.
In connection with the offering of our securities,
we may grant to the underwriters an option to purchase additional securities with an additional underwriting commission, as may be set
forth in the accompanying prospectus supplement. If we grant any such option, the terms of such option will be set forth in the prospectus
supplement for such securities.
If a dealer is used in the sale of our securities
in respect of which the prospectus is delivered, we will sell such securities to the dealer, as principal. The dealer, who may be deemed
to be an “underwriter” as that term is defined in the Securities Act, may then resell such securities to the public at varying
prices to be determined by such dealer at the time of resale.
If we offer securities in a subscription rights
offering to our existing security holders, we may enter into a standby underwriting agreement with dealers, acting as standby underwriters.
We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter
into a standby underwriting arrangement, we may retain a dealer-manager to manage a subscription rights offering for us.
Agents, underwriters, dealers and other persons
may be entitled under agreements which they may enter into with us to indemnification by us against certain civil liabilities, including
liabilities under the Securities Act, and may be customers of, engage in transactions with or perform services for us in the ordinary
course of business.
Certain agents, underwriters and dealers, and
their associates and affiliates, may be customers of, have borrowing relationships with, engage in other transactions with, or perform
services, including investment banking services, for us or one or more of our respective affiliates in the ordinary course of business.
In order to facilitate the offering of our securities,
any underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of our common stock or any other securities
the prices of which may be used to determine payments on such common stock or other securities. Specifically, any underwriters may over-allot
in connection with the offering, creating a short position for their own accounts. In addition, to cover overallotments or to stabilize
the price of the common stock or of any such other securities, the underwriters may bid for, and purchase, the common stock or any such
other securities in the open market. Finally, in any offering of our securities through a syndicate of underwriters, the underwriting
syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing our securities in the offering if the
syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions
or otherwise. Any of these activities may stabilize or maintain the market price of our securities above independent market levels. Any
such underwriters are not required to engage in these activities and may end any of these activities at any time.
We may engage in “at the market offerings”
within the meaning of Rule 415(a)(4) under the Securities Act, to or through a market maker or into an existing trading market on an exchange
or otherwise. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus
to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those
derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short
sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close
out any related open borrowings of securities, and may use securities received from us in settlement of those derivatives to close out
any related open borrowings of securities. The third party in such sale transactions will be an underwriter and, if not identified in
this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise
loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus
and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors
in our securities or in connection with a concurrent offering of other securities.
The specific terms of any lock-up provisions
in respect of any given offering will be described in the applicable prospectus supplement.
The underwriters, dealers and agents may engage
in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation.
The anticipated date of delivery of offered
securities will be set forth in the applicable prospectus supplement relating to each offer.
We will bear all costs, expenses and fees in
connection with the registration of the securities, as well as the expense of all commissions and discounts, if any, attributable to sales
of the securities by us.
DESCRIPTION OF SECURITIES
The following is a summary of the rights of
our common and preferred stock and our outstanding warrants, and some of the provisions of our amended and restated certificate of incorporation,
as amended, or our Certificate of Incorporation, and our amended and restated bylaws, or our Bylaws, and the Delaware General Corporation
Law, or the DGCL. Because it is only a summary, it does not contain all of the information that may be important to you. Such summary
is subject to and qualified in its entirety by our Certificate of Incorporation and our Bylaws, a copy of each of which has been incorporated
as an exhibit to the registration statement of which this prospectus forms a part.
Our common stock, par value $0.01 per share,
trading symbol OPGN is registered under Section 12(b) of the Securities Exchange Act of 1934, as amended.
General
We, directly or through one or
more underwriters, dealers and agents designated from time to time, or directly to purchasers, or through a combination of these methods,
may offer, issue and sell, together or separately, in one or more offerings, the following securities:
● shares
of our common stock;
● shares
of our preferred stock, in one or more series;
● warrants
to purchase shares of our common stock or preferred stock;
● units
consisting of any combination of the securities listed above, each on terms to be determined at the time of sale.
The preferred stock may also be exchangeable for and/or convertible
into shares of common stock, another series of preferred stock, or other securities. The common stock, preferred stock, warrants, and
units are collectively referred to in this prospectus as the “securities.” When a particular series of securities is offered,
a supplement to this prospectus will be delivered with this prospectus, which will set forth the terms of the offering and sale of the
offered securities.
Authorized Capital Stock
As of July 31, 2021, our authorized capital
stock consists of 50,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01
per share. As of July 31, 2021, 38,270,250 shares of our common stock are issued and outstanding and 10,981,518 shares of common are reserved
for future issuance upon exercise of outstanding stock options and warrants.
Common Stock
The holders of our common stock
are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do
not have any cumulative voting rights. Our Board of Directors are elected to a one year term; the Company does not have a staggered board.
Holders of our common stock are entitled to receive ratably any dividends declared by the Board of Directors out of funds legally available
for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights,
conversion rights or other subscription rights or redemption or sinking fund provisions.
In the event of our liquidation, dissolution
or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other
liabilities and any liquidation preference of any outstanding preferred stock.
Preferred Stock
Undesignated Preferred Stock
Our Board of Directors has the authority, without
further action by our stockholders, to issue from time to time 10,000,000 shares of preferred stock in one or more series. Our Board of
Directors will have the authority to establish the number of shares to be included in each series and fix the powers, preferences and
rights of the shares of each wholly unissued series and any of its qualifications, limitations or restrictions. Our Board of Directors
will also be able to increase or decrease the number of shares of any series, but not below the number of shares of that series then outstanding,
without any further vote or action by the stockholders.
The issuance of preferred stock could decrease
the amount of earnings and assets available for distribution to the holders of common stock or adversely affect the rights and powers,
including voting rights, of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with
possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a
change in control of our Company, which could depress the market price of our common stock.
Warrants
We may issue warrants, in one
or more series, for the purchase of our common stock or preferred stock. Warrants may be issued independently or together with our common
stock or preferred stock and may be attached to or separate from any offered securities.
A prospectus supplement accompanying
this prospectus relating to a particular series of warrants will describe the terms of those warrants, including:
● the
title and the aggregate number of warrants,
● the
security for which each warrant is exercisable,
● the
date or dates on which the right to exercise such warrants commence and expire,
● the
price or prices at which such warrants are exercisable,
● the
periods during which and places at which such warrants are exercisable,
● the
terms of any mandatory or optional call provisions,
● the
price or prices, if any, at which the warrants may be redeemed at the option of the holder or will be redeemed upon expiration,
● the
identity of the warrant agent, and
● the
exchanges, if any, on which such warrants may be listed, if any.
You should read the particular terms of the documents pursuant to
which the warrants will be issued, which will be described in more detail in the applicable prospectus supplement.
Outstanding Warrants
As of the date of this prospectus, we have outstanding warrants
to purchase shares of our common stock to various persons and entities, under which we could be obligated to issue up to 8,717,963 shares
of common stock, including:
|
|
·
|
986,931 shares of common stock issuable upon the exercise of outstanding warrants granted as of December
31, 2020, at a weighted average exercise price of $22.30 per share;
|
|
|
·
|
4,583,332 shares of common stock issuable upon the exercise of common warrants issued to purchasers
and placement agent in our registered direct offering in February 2021, at an exercise price of $3.55 per share; and
|
|
|
·
|
3,147,700 shares of common stock issuable upon the exercise of common warrants issued to purchasers
in our warrant exercise transaction in March 2021, at an exercise price of $3.56 per share.
|
Warrants issued in Bridge Financing
Pursuant to the Note Purchase Agreement and
the underlying transactions, the Company has issued warrants to purchase shares of its common stock to jVen Capital, LLC in an amount
equal to 20% of the principal of each of the two bridge financing notes issued, or the jVen Capital Warrants, and warrants to purchase
shares of its common stock to Merck Global Health Innovation Fund in an amount equal to 20% of an amended and restated note issued by
the Company to Merck Global Health Innovation Fund on June 28, 2017, the date of issuance. The warrants each have a five year term from
issuance, are first exercisable on the date that is six months after the date of issuance and have an exercise price equal to 110% of
the closing price of the Company’s common stock on the date immediately prior to the date of issuance. The terms of the warrants
issued in connection with such notes (other than the exercise price and the number of shares) may be amended, in the discretion of the
holder, to reflect the terms of the warrants issued in our public offering transaction in July 2017 described below.
The jVen Capital Warrants each include a blocker
provision that prevents the exercise of the jVen Capital Warrants if such exercise, when aggregated with the other issuances contemplated
under the Note Purchase Agreement, would violate Nasdaq Listing Rule 5635, unless stockholder approval is first obtained by the Company.
Warrants issued in the July 2017 Public Offering
The Company issued warrants in connection with
its public offering transaction in July 2017. The common warrants issued in the July 2017 public offering entitle the registered holder
to purchase one five-hundredths of a share of common stock at an exercise price of $212.50 per share. In addition, the Company issued
warrants to the placement agent that have an exercise price of $250.00 per share of common stock. All of the warrants issued in the July
2017 public offering were immediately exercisable and have a five-year term from the date of issuance.
Warrants issued in the February 2018 Public Offering
The Company issued warrants in connection with
its public offering transaction in February 2018. The common warrants issued in the February 2018 public offering entitle the registered
holder to purchase one-fortieth of a share of common stock at an exercise price of $65.00 per share. In addition, the Company issued warrants
to the placement agent that have an exercise price of $81.25 per share of common stock. All of the warrants issued in the February 2018
public offering are immediately exercisable and have a five-year term from the date of issuance.
Common Warrants in the October 2019 Offering
The following is a summary of certain terms
and provisions of the common warrants issued by us to purchasers and the placement agent in connection with our private placement offering
of units and pre-funded units in October 2019.
Duration and Exercise Price
Each common warrant included in the units and
the pre-funded units has an initial exercise price per share equal to $2.00. In addition, the Company issued warrants to the placement
agent that have an exercise price of $2.60 per share. The common warrants are immediately exercisable and will expire on the fifth anniversary
of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate
adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise
price. The common warrants were issued separately from the common stock included in the units, or the pre-funded warrants included in
the pre-funded units, as the case may be, and may be transferred separately.
Cashless Exercise
If, at the time a holder exercises its common
warrants, a registration statement registering the issuance of the shares of common stock underlying the common warrants under the Securities
Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated
to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise
(either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the common warrants.
Exercisability
The common warrants will be exercisable, at
the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for
the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below).
A holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more
than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days' prior notice from the holder
to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder's common warrants up to 9.99%
of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership
is determined in accordance with the terms of the common warrants.
Fractional Shares
No fractional shares of common stock will be
issued upon the exercise of the common warrants. Rather, the number of shares of common stock to be issued will, at our election, either
be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the exercise price.
Transferability
Subject to applicable laws, a common warrant
may be transferred at the option of the holder upon surrender of the common warrant to us together with the appropriate instruments of
transfer.
Trading Market
There is no trading market available for the
common warrants on any securities exchange or nationally recognized trading system.
Right as a Stockholder
Except as otherwise provided in the common warrants
or by virtue of such holder’s ownership of shares of our common stock, the holders of the common warrants do not have the rights
or privileges of holders of our common stock, including any voting rights, until they exercise their common warrants.
Fundamental Transaction
In the event of a fundamental transaction which
is within our control, the holders of the common warrants have the right to require us or a successor entity to redeem the common warrant
for cash in the amount of the Black-Scholes value of the unexercised portion of the common warrant on the date of the consummation of
the fundamental transaction. In the event of a fundamental transaction which not in our control, including a fundamental transaction that
is not approved by our Board, the holders of the common warrants have the right to require us or a successor entity to redeem the common
warrant for the consideration paid in the fundamental transaction in the amount of the Black Scholes value of the unexercised portion
of the common warrant on the date of the consummation of the fundamental transaction.
Common Warrants in February 2021 Offering
The following is a summary of certain terms
and provisions of the common warrants issued by us to purchasers and the placement agent in connection with our registered direct offering
of shares of common stock, common warrants and pre-funded warrants in February 2021.
Duration and Exercise Price
Each common warrant issued to purchasers has
an initial exercise price per share equal to $3.55. In addition, the Company issued warrants to the placement agent that have an exercise
price of $3.90 per share. The common warrants were exercisable on the six month anniversary of their issuance and will expire on the five-and-a-half
year anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject
to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock
and the exercise price. The common warrants were issued separately from the common stock or pre-funded warrants issued in the offering
and may be transferred separately.
Cashless Exercise
If, at the time a holder exercises its common
warrants, a registration statement registering the issuance of the shares of common stock underlying such warrants under the Securities
Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated
to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise
(either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the common warrants.
Exercisability
The common warrants will be exercisable, at
the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for
the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below).
A holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more
than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days' prior notice from the holder
to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder's common warrants up to 9.99%
of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership
is determined in accordance with the terms of the common warrants, as applicable.
Fractional Shares
No fractional shares of common stock will be
issued upon the exercise of the common warrants. Rather, the number of shares of common stock to be issued will, at our election, either
be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the exercise price.
Transferability
Subject to applicable laws, a common warrant
may be transferred at the option of the holder upon surrender of the warrant to us together with the appropriate instruments of transfer.
Trading Market
There is no trading market available for the
common warrants on any securities exchange or nationally recognized trading system.
Right as a Stockholder
Except as otherwise provided in the warrants
or by virtue of such holder’s ownership of shares of our common stock, the holders of the warrants do not have the rights or privileges
of holders of our common stock, including any voting rights, until they exercise their warrants.
Fundamental Transaction
In the event of a fundamental transaction which
is within our control, the holders of the common warrants have the right to require us or a successor entity to redeem the common warrant
for cash in the amount of the Black-Scholes value of the unexercised portion of the common warrant on the date of the consummation of
the fundamental transaction. In the event of a fundamental transaction which not in our control, including a fundamental transaction that
is not approved by our Board, the holders of the common warrants have the right to require us or a successor entity to redeem the common
warrant for the consideration paid in the fundamental transaction in the amount of the Black Scholes value of the unexercised portion
of the common warrant on the date of the consummation of the fundamental transaction.
Common Warrants in March 2021 Warrant Exercise Transaction
and November 2020 Placement Agent Warrants
In November 2020, the Company consummated a
private placement transaction of common stock that included the issuance of 4,842,615 common warrants to the purchaser and 242,130 common
warrants to the placement agent. In March 2021, the Company completed a warrant exercise transaction pursuant to which the purchaser exercised
the remaining common warrants in exchange for an aggregate amount of 3,147,700 warrants. The following is a summary of certain terms and
provisions of the common warrants issued by us in connection with our warrant exercise transaction in March 2021 as well as the common
warrants issued to the placement agent in connection with the private placement transaction in November 2020.
Duration and Exercise Price
Each common warrant issued in the warrant exercise
transaction has an initial exercise price per share equal to $3.56. In addition, the common warrants issued to the placement agent in
the November 2020 private placement that have an exercise price of $2.6845 per share. The common warrants were immediately exercisable
and expire on the five year anniversary of the original issuance date. The exercise price and number of shares of common stock issuable
upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting
our common stock and the exercise price.
Cashless Exercise
If, at the time a holder exercises its common
warrants, a registration statement registering the issuance of the shares of common stock underlying such warrants under the Securities
Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated
to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise
(either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the common warrants.
Exercisability
The common warrants will be exercisable, at
the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for
the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below).
A holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more
than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days' prior notice from the holder
to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder's common warrants up to 9.99%
of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership
is determined in accordance with the terms of the common warrants, as applicable.
Fractional Shares
No fractional shares of common stock will be
issued upon the exercise of the common warrants. Rather, the number of shares of common stock to be issued will, at our election, either
be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the exercise price.
Transferability
Subject to applicable laws, a common warrant
may be transferred at the option of the holder upon surrender of the warrant to us together with the appropriate instruments of transfer.
Trading Market
There is no trading market available for the
common warrants on any securities exchange or nationally recognized trading system.
Right as a Stockholder
Except as otherwise provided in the warrants
or by virtue of such holder’s ownership of shares of our common stock, the holders of the warrants do not have the rights or privileges
of holders of our common stock, including any voting rights, until they exercise their warrants.
Fundamental Transaction
In the event of a fundamental transaction which
is within our control, the holders of the common warrants have the right to require us or a successor entity to redeem the common warrant
for cash in the amount of the Black-Scholes value of the unexercised portion of the common warrant on the date of the consummation of
the fundamental transaction. In the event of a fundamental transaction which not in our control, including a fundamental transaction that
is not approved by our Board, the holders of the common warrants have the right to require us or a successor entity to redeem the common
warrant for the consideration paid in the fundamental transaction in the amount of the Black Scholes value of the unexercised portion
of the common warrant on the date of the consummation of the fundamental transaction.
Units
We may issue units consisting of one or more
warrants, shares of preferred stock, shares of common stock or any combination of such securities. The applicable prospectus supplement
will describe the terms of the units and of the securities comprising the units, including whether and under what circumstances the securities
comprising the units may be traded separately. You should read the particular terms of the documents pursuant to which the units will
be issued, which will be described in more detail in the applicable prospectus supplement.
Registration Rights
Investors’ Rights Agreement
Under the Third Amended and Restated Investors’
Rights Agreement, dated as of December 18, 2013, among the Company and certain investors, or the investors’ rights agreement, we
granted registration rights to the holders of shares acquired prior to our initial public offering, or their permitted transferees. These
rights are provided under the terms of the investors’ rights agreement, and include demand registration rights, short-form registration
rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations will be borne by us and all selling
expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. The investors’ rights agreement contains customary cross-indemnification provisions, under which we are obligated to
indemnify holders of registrable shares in the event of material misstatements or omissions in the registration statement attributable
to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. The registration rights granted
under the investors’ rights agreement will terminate at the earlier of the closing of a deemed liquidation event and when all of
the holders of registrable securities are eligible to be sold without restrictions under Rule 144 promulgated under the Securities Act
within any 90-day period.
Bridge Financing Registration Rights
In connection with the bridge financing the
Company entered into a registration rights agreement with jVen Capital and with MGHIF, pursuant to which the investors were granted certain
demand registration rights and piggyback registration rights in connection with subsequent registered offerings of the Company’s
common stock. The registrable securities include the shares of common stock underlying the warrants issued to jVen Capital and to MGHIF
under the terms of the bridge financing promissory notes.
Anti-Takeover Effects of Our Certificate of Incorporation, Bylaws
and Delaware Law
Our Certificate of Incorporation and Bylaws
include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us
and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our Board of Directors
rather than pursue non-negotiated takeover attempts. These provisions include the items described below.
Meetings of Stockholders
Our Certificate of Incorporation and Bylaws
provide that only the Chair of the Board, the Chief Executive Officer or a majority of the members of our Board of Directors then in office
may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted
upon at a special meeting of stockholders. Our Bylaws limit the business that may be conducted at an annual meeting of stockholders to
those matters properly brought before the meeting.
Advance Notice Requirements
Our Bylaws establish advance notice procedures
with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought
before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to
our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our
principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting
for the preceding year. Our Bylaws specify the requirements as to form and content of all stockholders’ notices. These requirements
may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.
Amendment to Certificate of Incorporation and Bylaws
Any amendment of our Certificate of Incorporation
must first be approved by a majority of our Board of Directors, and if required by law or our Certificate of Incorporation, must thereafter
be approved by a majority of the outstanding shares entitled to vote on the amendment, except that the amendment of the provisions relating
to stockholder action, board composition, limitation of liability and the amendment of our Certificate of Incorporation must be approved
by not less than 66 2/3% of the outstanding shares entitled to vote on the amendment, and not less than 66 2/3% of the outstanding shares
of each class entitled to vote thereon as a class. Our Bylaws may be amended by the affirmative vote of a majority of the directors then
in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of at least 66 2/3% of
the outstanding shares entitled to vote on the amendment, or, if our board of directors recommends that the stockholders approve the amendment,
by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a
single class.
Exclusive Jurisdiction for Certain Actions
Our Certificate of Incorporation provides that,
once our common stock is a “covered security,” unless we consent in writing to the selection of an alternative forum, the
Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on
our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees
to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law,
our certificate of incorporation or our bylaws, or (iv) any action asserting a claim against us governed by the internal affairs doctrine.
Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits
to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability
of similar exclusive forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings,
and it is possible that a court could rule that this provision in our certificate of incorporation is inapplicable or unenforceable. In
addition, this exclusive forum provision is intended to apply to claims arising under Delaware state law and would not apply to claims
brought pursuant to the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.
To the extent the provision could be construed to apply to such claims, there is uncertainty as to whether a court would enforce the provision
in such respect, and our stockholders will not be deemed to have waived compliance with federal securities laws and the rules and regulations
thereunder.
Section 203 of the Delaware General Corporation Law
We are subject to the provisions of Section 203
of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in
a “business combination” with an “interested stockholder” for a three-year period following the time that this
stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203,
a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:
|
|
·
|
before the stockholder became interested, our Board of Directors approved either the business combination
or the transaction which resulted in the stockholder becoming an interested stockholder;
|
|
|
·
|
upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder,
the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced,
excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee
stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or
|
|
|
·
|
at or after the time the stockholder became interested, the business combination was approved by our
Board of Directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of
the outstanding voting stock which is not owned by the interested stockholder.
|
Section 203 defines a business combination
to include:
|
|
·
|
any merger or consolidation involving the corporation and the interested stockholder;
|
|
|
·
|
any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or
more of the assets of the corporation;
|
|
|
·
|
subject to exceptions, any transaction that results in the issuance or transfer by the corporation of
any stock of the corporation to the interested stockholder;
|
|
|
·
|
subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and
|
|
|
·
|
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges
or other financial benefits provided by or through the corporation.
|
In general, Section 203 defines an interested
stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity
or person affiliated with or controlling or controlled by the entity or person.
Listing
Our common stock is listed on the Nasdaq Capital
Market under the symbol “OPGN.”
Transfer Agent and Registrar
The transfer agent and registrar for our common
stock is Philadelphia Stock Transfer, Inc. The transfer agent’s address is 2320 Haverford Rd., Suite 230, Ardmore, PA 19003.
LEGAL MATTERS
Certain legal matters with respect to the securities
offered hereby have been passed upon by Ballard Spahr LLP.
EXPERTS
The consolidated financial statements of OpGen,
Inc. and its subsidiaries as of December 31, 2020 and 2019, and for the years then ended, have been incorporated by reference herein in
reliance upon the report, also incorporated by reference herein, of CohnReznick LLP, an independent registered public accounting firm,
and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December 31, 2020 consolidated
financial statements contains an explanatory paragraph that states that the Company has experienced losses and negative cash flows from
operations since its inception, has an accumulated deficit, and has debt obligations which raise substantial doubt about its ability to
continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of
that uncertainty.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
We filed with the SEC a
registration statement under the Securities Act of 1933 for the Warrant Shares under this prospectus. This prospectus does not
contain all of the information in the registration statement and the exhibits and schedule that were filed with the registration
statement. For further information with respect to us and our securities, we refer you to the registration statement and the
exhibits and schedule that were filed with the registration statement. Statements contained in this prospectus about the contents of
any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and we
refer you to the full text of the contract or other document filed as an exhibit to the registration statement. The SEC maintains a
website that contains reports, proxy and information statements, and other information regarding registrants that file
electronically with the SEC. The address of the website is www.sec.gov.
We file periodic reports under
the Securities Exchange Act of 1934, including annual, quarterly and special reports, and other information with the Securities and Exchange
Commission. These periodic reports and other information are available for inspection and copying at the SEC regional offices, public
reference facilities and on the website of the SEC referred to above.
We make available free of charge on or through
our internet website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those
reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as soon as reasonably practicable
after we electronically file such material with, or furnish it to, the SEC. The information found on our website, www.opgen.com, other
than as specifically incorporated by reference in this prospectus, is not part of this prospectus.
INCORPORATION BY REFERENCE
The SEC allows us to “incorporate by reference”
in this prospectus the information in other documents that we file with it, which means that we can disclose important information to
you by referring you to those documents containing such information. This prospectus is part of a registration statement we filed with
the SEC. You should rely on the information incorporated by reference in this prospectus and the registration statement. The information
incorporated by reference is considered to be part of this prospectus and information we file later with the SEC will automatically update
and supersede this information and information contained in documents filed earlier with the SEC. We incorporate by reference the documents
listed below, any filings made with the SEC after the date of the initial registration statement and prior to effectiveness of the registration
statement, and any future filings made with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination
of the offering; provided, that we are not incorporating by reference any documents or information deemed to have been furnished and not
filed in accordance with SEC rules. The documents we are incorporating by reference are:
|
|
·
|
our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 29,
2021;
|
|
|
·
|
our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 14,
2021;
|
|
|
·
|
our Current Reports on Form 8-K filed with the SEC on February 10, 2021 (Items 1.01, 3.02, 8.01 and
9.01), March 8, 2021 (Items 5.02 and 8.01), March 9, 2021 (Items 1.01, 3.02 and 9.01), June 9, 2021 (Items 5.07, 8.01 and 9.01), July
7, 2021 (Items 8.01 and 9.01), July 29, 2021 (Item 5.02), and August 5, 2021 (Item 8.01 and 9.01);
|
|
|
·
|
our proxy statement for the Annual Meeting of Stockholders to be held on June 9, 2021, filed with the
SEC on April 26, 2021; and
|
|
|
·
|
the description of our Common Stock contained in the Registration Statement on Form 8-A filed on April
30, 2015 and any amendments to such Registration Statement filed subsequently thereto, including all amendments or reports filed for the
purpose of updating such description.
|
We will furnish to you, on written or oral request, a copy of any
or all of the documents that have been incorporated by reference, including exhibits to these documents. You may request a copy of these
filings at no cost by writing or telephoning our Secretary at the following address and telephone number:
OpGen, Inc.
Attention: Timothy C. Dec, Corporate Secretary
9717 Key West Avenue, Suite 100
Rockville, MD 20850
Telephone No.: (240) 813-1260
prospectus
, 2021
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The costs and expenses payable by the Company
in connection with the offerings described in this registration statement are as follows:
|
SEC registration fee
|
|
|
$16,365.00
|
|
|
Legal fees and expenses
|
|
|
*
|
|
|
Accounting fees and expenses
|
|
|
*
|
|
|
Printer costs and expenses
|
|
|
*
|
|
|
Total
|
|
|
*
|
|
_____________
* These fees depend on the number of issuances and amount of securities
sold and accordingly cannot be estimated at this time.
Item 15. Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation
Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and
proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving
as a director or officer to a corporation. The indemnity may cover expenses (including attorneys’ fees) judgments, fines and amounts
paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding.
Section 145 permits corporations to pay expenses (including attorneys’ fees) incurred by directors and officers in advance of the
final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and
maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity
as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the
director or officer against such liability under Section 145.
We have adopted provisions in our certificate
of incorporation and bylaws that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL,
as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for
monetary damages or breach of fiduciary duty as a director, except for liability for:
|
|
·
|
any breach of the director’s duty of loyalty to us or our stockholders;
|
|
|
·
|
any act or omission not in good faith or that involves intentional misconduct or a knowing violation
of law;
|
|
|
·
|
any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions;
or
|
|
|
·
|
any transaction from which the director derived an improper personal benefit.
|
These limitations of liability do not alter
director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or
rescission.
In addition, our bylaws provide that:
|
|
·
|
we will indemnify our directors, officers and, in the discretion of our board of directors, certain
employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and
|
|
|
·
|
we will advance reasonable expenses, including attorneys’ fees, to our directors and, in the discretion
of our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or
on behalf of us, subject to limited exceptions.
|
We have entered into indemnification agreements
with each of our directors and executive officers. These agreements provide that we will indemnify each of our directors, such executive
officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys’
fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection
with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding
arising out of that person’s services as a director or officer brought on behalf of us and/or in furtherance of our rights. Additionally,
each of our directors may have certain rights to indemnification, advancement of expenses and/or insurance provided by their affiliates,
which indemnification relates to and might apply to the same proceedings arising out of such director’s services as a director referenced
herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors are primary and any
obligation of the affiliates of those directors to advance expenses or to provide indemnification for the expenses or liabilities incurred
by those directors are secondary.
We also maintain general liability insurance
which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as
directors or officers, including liabilities under the Securities Act.
A stockholder’s investment may be adversely
affected to the extent we pay the costs of settlement and damage awards against directors and officers as required by these indemnification
provisions. At present, there is no pending litigation or proceeding involving any of our directors, officers or employees regarding which
indemnification is sought, nor are we aware of any threatened litigation that may result in claims for indemnification.
Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have
been informed that, in the opinion of the SEC, this indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable.
Item 16. Exhibits.
The following exhibits are filed as part of,
or incorporated by reference into this registration statement:
|
Exhibit Number
|
Identification of Exhibit
|
|
1.1 +
|
Form of Underwriting Agreement
|
|
3.1
|
Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of Current Report on Form 8-K, filed on May 13, 2015)
|
|
3.2
|
Certificate of Correction to Amended and Restated Certificate of Incorporation of OpGen, Inc., filed June 6, 2016 (incorporated by reference to Exhibit 3.1 of Current Report on Form 8-K, filed on June 6, 2016)
|
|
3.3
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant dated and filed with the Delaware Secretary of State on January 17, 2018 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on January 17, 2018)
|
|
3.4
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of the Registrant dated and filed with the Delaware Secretary of State on August 28, 2019 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on August 28, 2019)
|
|
3.5
|
Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of Form S-1, filed on March 3, 2015)
|
|
3.6
|
Amendment to the Amended and Restated Bylaws of OpGen, Inc., dated August 5, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on August 11, 2020).
|
|
4.1
|
Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2018, filed on February 27, 2019)
|
|
4.2
|
Form of Common Stock Purchase Warrant for July 2017 Public Offering (incorporated by reference to Exhibit 4.4 to the Registrant’s Form S-1, Amendment No. 2, File No. 333-218392, filed on July 11, 2017)
|
|
4.3
|
Form of Placement Agent Warrant for July 2017 Public Offering (incorporated by reference to Exhibit 4.5 to the Registrant’s Form S-1/A, File No. 333-218392, filed on July 11, 2017)
|
|
4.4
|
Form of Warrant to Purchase Common Stock (issued to jVen Capital, LLC and Merck Global Health Innovation Fund) (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K Amendment No. 2, filed on July 10, 2017)
|
|
4.5
|
Form of Common Stock Purchase Warrant for February 2018 Public Offering (incorporated by reference to Exhibit 4.3 to the Registrant’s Form S-1/A, File No. 333-222140, filed on January 31, 2018)
|
|
4.6
|
Form of Pre-Funded Common Stock Purchase Warrant for February 2018 Public Offering (incorporated by reference to Exhibit 4.4 to the Registrant’s Form S-1/A, File No. 333-222140, filed on January 31, 2018)
|
|
4.7
|
Form of Placement Agent Warrant for February 2018 Public Offering (incorporated by reference to Exhibit 4.5 to the Registrant’s Form S-1/A, File No. 333-222140, filed on January 31, 2018)
|
|
4.8
|
Form of Pre-funded Warrant (incorporated by reference to Exhibit 4.9 to the Registrant's Registration Statement on Form S-1, Amendment No. 1, File No. 333-233775, filed on October 15, 2019)
|
|
4.9
|
Form of Underwriter’s Warrant (incorporated by reference to Exhibit 4.10 to the Registrant’s Registration Statement on Form S-1, Amendment No. 1, File No. 333-233775, filed on October 15, 2019)
|
|
4.10
|
Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.11 to the Registrant’s Registration Statement on Form S-1, Amendment No. 1, File No. 333-233775, filed on October 15, 2019)
|
|
4.11
|
Form of Placement Agent Warrant for 2020 PIPE (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on November 24, 2020).
|
|
4.12
|
Form of Common Stock Purchase Warrant for February 2021 Offering (incorporated by reference to Exhibit 4.2 to the Registrants, Current Report on Form 8-K, filed on February 10, 2021)
|
|
4.13
|
Form of Pre-Funded Common Stock Purchase Warrant for February 2021 Offering (incorporated by reference to Exhibit 4.1 to the Registrants, Current Report on Form 8-K, filed on February 10, 2021)
|
|
4.14
|
Form of New Warrant for March 2021 Warrant Exercise Transaction (incorporated by reference to Exhibit 4.1 to the Registrants, Current Report on Form 8-K, filed on March 9, 2021)
|
|
5.1 *
|
Opinion of Ballard Spahr LLP (incorporated by reference to Exhibit 5.1 to the Registration Statement on Form S-3, File No. 333-236106, filed on January 28, 2020).
|
|
23.1 *
|
Consent of CohnReznick LLP
|
|
23.2 *
|
Consent of Ballard Spahr LLP (included in Exhibit 5.1)
|
|
24.1
|
Power of Attorney (on signature page)
|
_____________
+ To
be filed, if applicable, as an exhibit to a report filed pursuant to Sections 13(a), 13(c) or 15(d) of the Exchange Act or by post-effective
amendment to the Registration Statement if securities are sold through one or more underwriters.
* Filed
herewith.
Item 17. Undertakings.
(a)
The undersigned registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to
this registration statement:
(i)
To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
in the information in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the
aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the
“Calculation of Registration Fee” table in the effective registration statement; and
(iii)
To include any material information with respect to the plan of distribution not previously disclosed
in the registration statement or any material change to such information in the registration statement;
Provided, however, that:
Paragraphs (1)(i), (1)(ii) and (1)(iii) of this
section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports
filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that
are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that
is part of the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered
which remain unsold at the termination of the offering.
(4)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
(i)
(i) If the registrant is relying on Rule 430B:
(A)
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of
the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and
(B)
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing
the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration
statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of
sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating
to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof, provided, however, that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such effective date; or
(ii)
If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part
of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness, provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such date of first use.
(5)
That, for the purpose of determining liability of the registrant under the Securities Act of 1933
to any purchaser in the initial distribution of the securities:
The undersigned registrant undertakes that in
a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to
such purchaser:
(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required
to be filed pursuant to Rule 424;
(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned
registrant or used or referred to by the undersigned registrant;
(iii)
The portion of any other free writing prospectus relating to the offering containing material information
about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the
purchaser.
(b)
The undersigned registrant hereby further undertakes that, for purposes of determining any liability
under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section
15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has
been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed
in the Securities Act of 1933, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as
expressed in said act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form
S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Rockville, State of Maryland on the 9th day of August, 2021.
|
|
OpGen, Inc.
|
|
|
By:
|
/s/ Timothy C. Dec
|
|
|
|
Timothy C. Dec
Chief Financial Officer and Secretary
(principal financial officer and principal accounting officer)
|
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS,
that each person whose signature appears below constitutes and appoints each of Oliver Schacht, Ph.D. and Timothy C. Dec as true and lawful
attorney-in-fact and agent, with full power of substitution and re-substitution, for them and in their name, place and stead, in any and
all capacities, to sign any and all amendments (including pre-effective and post-effective amendments) to this registration statement
and any additional registration statements filed pursuant to Rule 462, and to file the same, with all exhibits thereto, and other documents
in connection therewith, with the Securities and Exchange Commission (the SEC), and generally to do all such things in their names and
behalf in their capacities as officers and directors to enable the Company to comply with the provisions of the Securities Act of 1933
and all requirements of the SEC, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and
every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might
or could do in person, ratifying and confirming all that said attorney-in-fact and agent, or their or his or her substitutes or substitute,
may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act
of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
|
SIGNATURE
|
|
TITLE
|
|
DATE
|
|
|
|
|
|
|
/s/ Oliver Schacht, Ph.D.
Oliver Schacht, Ph.D.
|
|
Chief Executive Officer and Director
(principal executive officer)
|
|
August 9, 2021
|
|
|
|
|
|
|
/s/ Timothy C. Dec
Timothy C. Dec
|
|
Chief Financial Officer (principal financial officer and principal accounting officer)
|
|
August 9, 2021
|
|
|
|
|
|
|
|
/s/ Mario Crovetto
|
|
Director
|
|
August 9, 2021
|
|
Mario Crovetto
|
|
|
|
|
|
|
|
|
|
|
|
/s/ R. Donald Elsey
|
|
Director
|
|
August 9, 2021
|
|
R. Donald Elsey
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Prabhavathi Fernandes, Ph.D.
|
|
Director
|
|
August 9, 2021
|
|
Prabhavathi Fernandes, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
/s/ William Rhodes
|
|
Director
|
|
August 9, 2021
|
|
William Rhodes
|
|
|
|
|
|
|
|
|
|
|
II-6
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
